ALVO - Alvotech rises as biosimilar to Regeneron's Eylea succeeds in trial
2024-01-03 06:43:17 ET
More on Alvotech, Regeneron, etc.
- Regeneron Pharmaceuticals Inc. (REGN) American Society of Hematology 2023 Investor Conference - (Transcript)
- Alvotech: Biosimilars Portfolio Opportunity Is High Risk
- Alvotech (ALVO) Q3 2023 Earnings Call Transcript
- Regeneron expands battle over Eylea patents in new lawsuit against Samsung Bioepis
- Regeneron gains after mixed ruling in patent suit over Eylea vs Viatris (update)
For further details see:
Alvotech rises as biosimilar to Regeneron’s Eylea succeeds in trial